Name Change Announced for Female Condom Product

Chicago, Sept. 19, 2001- The Female Health Company announced today the establishment of FC Female Condom Ò as the Company’s worldwide trademark for its female condom.  The Company has previously sold the female condom as REALITY to consumers in the US.   According to the Company’s President, Dr. Mary Ann Leeper, the objective is to create a worldwide single mark identity for the female condom.  She noted that in addition this will result in cost and expense savings.  The female condom will continue to be called Femidom, MyFemy and Femy by distributors in certain other countries.

The Female Condom is the only product controlled by women that helps to prevent STDs, including HIV/AIDS and unintended pregnancy.  The Female Condom is made of polyurethane, which is strong and unlikely to rip or tear during use and unlikely to cause allergic reactions.  It is manufactured in a state of the art facility in London, England.

The Female Health Company, based in Chicago, owns certain worldwide rights to The Female Condomä, including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of China, Canada, New Zealand, South Korea and Australia.

“Safe Harbor” Statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company’s current plans and strategies, and reflect the Company’s current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of governmental regulations, both in the United States and abroad; the effects of competitive products and pricing pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company’s press releases, shareholder communication and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company’s operations may vary from those currently anticipated.

Contacts:        Investors                        Business / Product               Global Program         

                        William R. Gargiulo, Jr.     Mary Ann Leeper, Ph.D.           Mitchell Warren

                        231.526.1244                     312.280.1119 x223                    845-353-8298